BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT

• Main Authors: Ivana Inić, Momcilo Inić, Zorka Inić, Milan Zegarac, Aleksandar Martinović, Miomir Šašić, Miloš Bracanović, Gordana Pupić
• Format: Article
• Language: English
• Published: University in Nis, Faculty of Medicine 2014-09-01
• Series: Acta Medica Medianae
• Subjects: metastatic melanoma; BRAF V600 mutation; treatment
• Online Access: http://publisher.medfak.ni.ac.rs/2014-html/3-broj/Ivana%20Inic-BRAF.pdf
• ISSN: 0365-4478; 1821-2794

The treatment of metastatic melanoma represents a challenge. Vemurafenib, a selective BRAF kinase inhibitor, is a new medicine against carcinoma. Recently, it has been shown that it raises the survival rate among patients with metastatic melanoma who have BRAFV600mutation. This work will discuss new approaches to the treatment of patients with metastatic melanoma, who have been proved to have BRAF V600 mutation and we will present the case of a female patient with whom the clinical study with Vemurafenib has been started.